HomeClinical ResearchCurrent Clinical Trails A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
TAS 120 301
Condition: advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements | Last Updated: | Status: